National Jewish Health

About: National Jewish Health is a healthcare organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: T cell & Asthma. The organization has 883 authors who have published 833 publications receiving 79201 citations. The organization is also known as: National Jewish Medical and Research Center.

Opioid crisis: a public health concern in Colorado, United States

Abstract: Opioids have become one of the leading substances abused across many cities in the United States (US), with opioid use disorder already a public health concern. Most of the opioid-related deaths are due to prescription medication. In 2017, opioid overdose was responsible for 560 deaths in Colorado, representing 5.8 deaths per 100,000 residents. Women and children are increasingly affected, implying a need for concerted efforts to address it. Despite an alarming rate of opioid crisis among pregnant women, direct health consequences, especially Neonatal Abstinence Syndrome (NAS), are not clearly covered by health insurance schemes in Colorado, which significantly affects care and overall public health response. In this paper, the impact of opioids on maternal and child health in Colorado is examined, with recommendations towards improving overall management response.

Marker for cancer prognosis and methods related thereto

Abstract: The present invention is related to the novel discovery that HIF-2α, but not HIF-1α, selectively regulates adenosine A2A receptor in endothelial cells, thereby revealing a unique and hitherto unknown pathway by which HIF-2α can regulate angiogenesis independent of HIF-1α. This discovery allows for design of new diagnostic tools and novel therapies targeted against angiogenesis-associated diseases, such as cancer. In another aspect, the present invention shows that A2A receptor expression is a marker of the developing lung, and can be used as a marker of lung diseases, such as pulmonary hypertension.

Using Cytokine Reporter Mice to Visualize Type-2 Immunity In Vivo

Abstract: Type-2 cytokine production plays a critical role in the context of type 2 immunity and allergic inflammation. Interleukin-4 (IL-4) and IL-13 are key modulators of the cell-mediated and humoral immune hallmarks most commonly associated with type-2 immune responses. However, production of these cytokines by lymphocytes and their tissue localization has been difficult to detect in vivo. As such, the field has relied heavily on ex vivo restimulation and in vitro differentiation assays to understand type-2 cytokine biology. Although these studies have greatly informed our understanding of type-2 cytokine regulation, it is becoming increasingly clear that the data does not always provide a true accounting of the complexity of type-2 immune cell biology in vivo. Described below is a protocol used to detect IL-4-competent and protein-producing cells in the lung and lymph nodes of mice after infection with a helminth. Importantly, this protocol has also been used to successfully identify reporter expression and cell function in vivo using various other cytokine-reporter systems.